Brian L Hoh, MD, MBA, FACS, FAHA, FAANS

My name is Brian Hoh, MD, MBA, and I am chair of the UF Department of Neurosurgery. I specialize in the treatment of brain aneurysms, arteriovenous malformations, ischemic and hemorrhagic stroke, cavernous malformations, carotid stenosis, moyamoya disease, hydrocephalus, Chiari malformation, brain cysts and brain tumors, including meningiomas, glioblastoma and astrocytomas.

I joined the UF Department of Neurosurgery in 2006. Before that, I graduated with a bachelor’s degree from Stanford University and a medical degree from Columbia University. I completed my internship in surgery, residency in neurosurgery, and fellowship in endovascular neurosurgery and interventional neuroradiology at Harvard University’s teaching hospital, Massachusetts General Hospital. I later attended UF business school and graduated with an MBA in 2019.

In addition to taking care of patients, I conduct NIH-funded laboratory and clinical research to improve biomedical advances in care. My laboratory investigates the biological mechanisms of brain aneurysm formation and rupture, innovative tissue engineering technology to improve the treatment of brain aneurysms, and the pathophysiology of acute neural injury and delayed cerebral ischemia after subarachnoid hemorrhage.

The NIH awarded me a $38 million grant to lead a large national clinical trial, Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA). With CAPTIVA, we are investigating rivaroxaban or ticagrelor versus clopidogrel for preventing stroke in patients with symptomatic 70% or greater intracranial atherosclerotic stenosis.

As a national leader in neurosurgery, I have served as president of the Congress of Neurological Surgeons, chair of the Joint American Association of Neurological Surgeons/Congress of Neurosurgical Surgeons Cerebrovascular Section, co-chair of the editorial board of the Journal of Neurosurgery and a past member of the editorial board of World Neurosurgery.

In my free time, I enjoy spending time with my family, rooting for the Gators and playing golf.

• Endovascular Neurosurgery

  American Board of Neurological Surgery Recognition of Focused Practice
• Neurological Surgery

  American Board of Neurological Surgery

My research includes basic, translational, and clinical research in cerebrovascular diseases, in particular stroke, cerebral aneurysms, and subarachnoid hemorrhage. My research has been supported by continuous NIH funding since 2009. I have successfully translated NIH K08 faculty funding to NIH R01 and U01 funding. In 2021, I was the #1 highest NIH-funded neurosurgeon according to Blue Ridge Institute for Medical Research.

My research is focused on studying:

1) the basic mechanisms of cerebral aneurysm repair: NIH R01 NS083673 (PI: B. Hoh, 2014-19), NIH K08 NS067058 (PI: B. Hoh, 2009-14), NIH LRP (2009-14)

2) inflammatory pathways for cerebral aneurysm formation and rupture: NIH R01 NS110710 (PI: B. Hoh, 2020-24), NIH R56 NS110710 (PI: B. Hoh, 2019-20)

3) mechanisms for acute neural injury after subarachnoid hemorrhage: NIH R01 NS124620 (PI: B. Hoh, 2022-2027)

4) anti-thrombotics to prevent recurrent stroke from symptomatic intracranial atherosclerotic stenosis: U01 NS117450 (multi-PI: B. Hoh, M. Chimowitz, 2021-2026)

5) pterygopalatine fossa nerve blockade for acute headache treatment in subarachnoid hemorrhage patients: NIH U01NS124613 (pending, multi-PI: K. Busl, C. Maciel, C. Smith, B. Hoh, M. Fava, A. Troxel)

My expertise in the field is recognized as I am the chair of the writing group for the American Heart Association/American Stroke Association’s Guidelines on the Management of Aneurysmal Subarachnoid Hemorrhage (SAH), and I have been on the writing groups for the American Heart Association/American Stroke Association’s Guidelines on the Management of Acute Ischemic Stroke, the Neurocritical Care Society’s Guidelines on the Critical Care Management of Patients Following Aneurysmal SAH, and the American College of Radiology’s Appropriateness Criteria on Cerebrovascular Disease.

Ongoing and recently completed projects that I would like to highlight include:

NIH U01 NS117450 Hoh and Chimowitz (multi-PIs) 2021-2025 CAPTIVA (Comparison of Anti- coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis)

NIH R01 NS124620 Hoh (PI) 2022-2027 Neurovascular Protection by Adropin in Acute Neural Injury from Subarachnoid Hemorrhage

NIH R01 and R56 NS110710 Hoh (PI) 2019-2024 Inflammatory Mediators and Mechanisms of Cerebral Aneurysm Formation and Rupture

NIH R01 NS083673 Hoh (PI) 2014-2019 Cerebral Aneurysm Healing: Cellular Mediators, Mechanisms, and Downstream Actions

NIH R25 NS108939 Okun and Hoh (PIs) 2019-2024 University of Florida R25 Early Research Program for Neurology and Neurosurgery Residents

Citations:

Hoh BL, Hosaka K, Downes DP, Nowicki KW, Fernandez CE, Batich CD, Scott EW. Monocyte chemotactic protein-1 promotes inflammatory vascular repair of murine carotid aneurysms via a macrophage inflammatory protein-1α and macrophage inflammatory protein-2-dependent pathway. Circulation. 2011 Nov 15;124(20):2243-52. PMID: 22007074

Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators: Stenting Versus Aggressive Medical Therapy for Intracranial Arterial Stenosis. New England Journal of Medicine 365(11): 993-1003, 2011. PMID 21899409

Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Lynch JR, Zaidat OO, Rumboldt Z, Cloft HJ; for the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators: Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 2014 Jan 25;383(9914):333-341. PMID 24168957

Waters MF, Hoh BL, Lynn MJ, Kwon HM, Turan TN, Derdeyn CP, Fiorella D, Khanna A, Sheehan TO, Lane BF, Janis S, Montgomery J, Chimowitz MI; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial Investigators: Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS trial. JAMA Neurology 2016 Mar;73(3):308-315. PMID 26747792

• Adult Brain Tumors
• Aneurysm Clipping
• Carotid Endarterectomy
• EC-IC bypass for complex aneurysm, ischemic stroke and Moyamoya disease
• Resection of intracranial arteriovenous malformations
• Resection of spinal arteriovenous malformations
• craniotomy